(Q44104691)

29 November 2017

title

Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing (English)

1 reference

29 November 2017

main subject

piperacillin/tazobactam

1 reference

1 reference

1 reference

David S Burgess

1

1 reference

29 November 2017

Travis Waldrep

series ordinal

2

1 reference

29 November 2017

publication date

1 July 2002

1 reference

29 November 2017

published in

Clinical Therapeutics

1 reference

29 November 2017

volume

24

1 reference

29 November 2017

issue

7

1 reference

29 November 2017

page(s)

1090-1104

1 reference

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Intermittent and continuous ceftazidime infusion for critically ill trauma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Prediction of creatinine clearance from serum creatinine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Determination of tazobactam and piperacillin in human plasma, serum, bile and urine by gradient elution reversed-phase high-performance liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Continuous infusion of beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Therapeutic efficacy of continuous versus intermittent administration of ceftazidime in an experimental Klebsiella pneumoniae pneumonia in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Continuous versus intermittent administration of ceftazidime in experimental Klebsiella pneumoniae pneumonia in normal and leukopenic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Continuous infusion ceftazidime in intensive care: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Cure of Pseudomonas aeruginosa infection in neutropenic patients by continuous infusion of ceftazidime

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Low-dose continuous-infusion ceftazidime monotherapy in low-risk febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Pharmacokinetics of meropenem in serum and suction blister fluid during continuous and intermittent infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

In vitro synergistic activities of tobramycin and selected beta-lactams against 75 gram-negative clinical isolates

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Pharmacokinetics and pharmacodynamics of aztreonam and tobramycin in hospitalized patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2802%2980021-2

7 January 2021

10.1016/S0149-2918(02)80021-2

Identifiers

DOI

1 reference

release_4bijc7avfvaillkdvzsszpl5mi

29 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4bijc7avfvaillkdvzsszpl5mi

24 November 2022

mapped directly with Wikidata item

1 reference